ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Codexis And Dyadic In Enzyme Dispute

by Melody M. Bomgardner
August 12, 2013 | APPEARED IN VOLUME 91, ISSUE 32

Industrial enzyme firm Codexis has received notice from Dyadic International that it is in violation of the terms of its license for Dyadic’s C1 fungal expression technology. Codexis uses the licensed technology to make its CodeXyme cellulase enzymes, which are aimed at producing biofuels. Dyadic has threatened to terminate the agreement in 60 days if the companies do not come to terms. Codexis contends it is not in breach of the agreement. The firm developed the cellulase enzyme during a multiyear partnership with Shell, which now has a sublicense to the technology. Codexis is looking for a new partner and says the disagreement may interfere with those discussions.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment